Mergermarket Uncovers Some Interesting M&A Data
Mergermarket has released its Global Pharma, Medical & Biotech trend report for the first half (H1) of 2014. Take a look at the full report HERE.
A few key findings include:
- Global Pharma, Medical & Biotech (PMB) M&A activity during H1 2014 hit the highest half-year value on Mergermarket record (since 2001), with US$ 260.2bn-worth of deals, a 227.8% increase from H1 2013 (US$ 79.4bn). The value so far in 2014 is already higher than the annual value for the last eight years. Q2 2014, which saw the announcement of 277 deals valued at US$ 195bn, increased values by 199.5% from Q2 2013 (US$ 65.1bn) and by 199% from the previous quarter (US$ 65.2bn)
- The massive increase is mainly due to the announcement of six mega-deals so far this year amounting to a combined total of US$ 156.9bn, versus two announced in H1 2013 totaling just US$ 27.4bn. The mega-deals all accounted for 60.3% of the total activity in the sector. The top two deals, each valued over US$ 45bn, represent the fifth and sixth highest valued PMB deal record
- PMB (only the fifth most active sector in Q1 2014 as well as in H1 last year) was the most active sector globally and accounted for 16.4% of the global M&A value (US$ 1,582.9bn). A stark contrast to a 7.9%a market share in H1 2013
Photo: biosantee.com